eif-3.G Antibody

What is eIF-3.G and what are its primary functions in cellular processes?

eIF-3.G functions as an RNA-binding component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in protein synthesis initiation. The eIF-3 complex associates with the 40S ribosome and facilitates the recruitment of eIF-1, eIF-1A, eIF-2:GTP:methionyl-tRNAi, and eIF-5 to form the 43S pre-initiation complex. Additionally, eIF-3.G plays critical roles in mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. It also contributes to the disassembly and recycling of post-termination ribosomal complexes and prevents premature joining of the 40S and 60S ribosomal subunits prior to initiation . Recent research has shown that eIF-3.G can selectively shape the neuronal protein landscape by interacting with specific mRNAs enriched in activity-dependent functions .

How is eIF-3.G structure organized and which domains are functionally important?

eIF-3.G contains several functionally critical domains, including an RNA recognition motif (RRM) and a zinc finger (ZF) domain. According to research using C. elegans models, the zinc finger domain plays a particularly important role in mRNA binding specificity. A missense mutation (C130Y) in the conserved zinc finger of EIF-3.G has been found to act in a gain-of-function manner that can modulate neuronal excitation . The RRM domain is essential for direct RNA interaction, as demonstrated by studies where deletion of this domain (ΔRRM) significantly reduces RNA binding capacity while maintaining protein expression .

Which model organisms are suitable for eIF-3.G research, and how conserved is this protein?

eIF-3.G is highly conserved across eukaryotes, making multiple model organisms suitable for research. Commercial antibodies show reactivity across numerous species including human, mouse, rat, dog, cow, pig, horse, guinea pig, zebrafish, and even bat . C. elegans has been effectively used as a model organism for studying eIF-3.G function in neuronal contexts, revealing mechanisms that appear to be conserved in mammals based on comparative analyses of 5'UTR binding patterns between C. elegans EIF-3.G and human eIF3g from HEK293 cells .

What criteria should researchers consider when selecting an eIF-3.G antibody for their experiments?

When selecting an eIF-3.G antibody, researchers should consider:

• Epitope specificity: Choose antibodies that target functionally relevant regions. For example, antibodies targeting amino acids 51-150 will recognize the middle region, which may have different experimental outcomes than those targeting the N-terminal (AA 1-320) or C-terminal regions .

• Host species and clonality: Both monoclonal (e.g., [EPR16147]) and polyclonal antibodies are available. Monoclonal antibodies offer higher specificity but potentially lower sensitivity compared to polyclonal options .

• Validated applications: Ensure the antibody has been validated for your specific application (WB, ICC/IF, IHC, IP, etc.) .

• Species reactivity: Confirm cross-reactivity with your experimental model. Some antibodies are human-specific, while others react with multiple species .

• Recognition of post-translational modifications: Consider whether your research questions require detection of specific modified forms of eIF-3.G.

How can researchers validate the specificity of an eIF-3.G antibody?

Proper validation of eIF-3.G antibodies should include multiple approaches:

• Western blot analysis: Confirm a single band at the expected molecular weight (~42-44 kDa for eIF-3.G) .

• Immunoprecipitation-Western blot: Use commercial anti-eIF3D antibodies to probe immunoprecipitates as a confirmation method. Research has shown that immunoprecipitates from patient samples containing anti-eIF3 autoantibodies display strong bands at the correct molecular weight when probed with commercial anti-eIF3D, while control samples do not .

• Pre-absorption controls: Pre-incubate the antibody with purified antigen before staining to confirm specificity.

• RNA interference or knockout controls: Compare staining between wild-type samples and those with reduced eIF-3.G expression.

• Mass spectrometry confirmation: For ultimate validation, use mass spectrometry to confirm the identity of immunoprecipitated proteins, as demonstrated in autoantigen identification studies .

What are the expected molecular weights and banding patterns for eIF-3.G in Western blotting?

In Western blotting applications, eIF-3.G typically appears as a band at approximately 42-44 kDa. When studying the entire eIF3 complex through immunoprecipitation, researchers should expect to see multiple bands corresponding to different eIF3 subunits. Studies have demonstrated the presence of bands at 37, 38, 40, 42, 66, 95, and 110 kDa, corresponding to eIF3G, eIF3I, eIF3H, eIF3E/F, eIF3L/D, eIF3B, and eIF3A, respectively . Verification through mass spectrometry has confirmed these identifications in previous research.

Which applications are most suitable for detecting and studying eIF-3.G?

Based on validated antibody applications, the following methodologies are most suitable for eIF-3.G research:

Most commercial antibodies are validated for multiple applications, with Western blotting and immunofluorescence being the most consistently reliable methods across different antibody products .

How can researchers optimize immunoprecipitation protocols for studying eIF-3.G and its interactions?

For optimal immunoprecipitation of eIF-3.G:

• Buffer optimization: Use buffers containing 0.1-0.5% NP-40 or Triton X-100 to maintain complex integrity without disrupting interactions.

• Cross-linking consideration: For studying RNA-protein interactions, implement UV cross-linking methods as demonstrated in seCLIP (single-end eCLIP) protocols. This approach has successfully identified eIF-3.G binding to 5'UTRs of specific mRNAs .

• Antibody selection: Choose antibodies specifically validated for immunoprecipitation. Rabbit recombinant monoclonal antibodies such as EPR16147 have shown high efficiency in IP applications .

• Controls: Always include isotype controls and, when possible, samples depleted of the target protein (e.g., using RNAi or CRISPR knockout) to identify non-specific binding.

• Validation: Confirm the identity of immunoprecipitated proteins by Western blotting with a different antibody or by mass spectrometry analysis, as demonstrated in autoantigen identification studies .

What are the recommended protocols for RNA-protein interaction studies involving eIF-3.G?

For studying RNA-protein interactions involving eIF-3.G:

• seCLIP (single-end enhanced CLIP): This specialized protocol has been effectively used to map EIF-3.G-mRNA interactions in neurons. The method involves:

  • UV cross-linking to stabilize RNA-protein interactions

  • Immunoprecipitation using anti-tag antibodies (e.g., anti-FLAG)

  • RNA fragmentation and library preparation

  • Sequencing and computational analysis to identify binding sites

• Footprinting analysis: Define specific footprints by comparing wild-type eIF-3.G binding patterns with those of truncated versions (e.g., ΔRRM) to identify direct binding events .

• Controls and validation: Include appropriate controls such as truncated eIF-3.G lacking the RNA-binding domain and IgG-only immunoprecipitations. In previous research, specific footprints were defined as clusters of at least 20 high-quality reads with at least 1.5-fold change enrichment over input controls .

How does eIF-3.G contribute to selective mRNA translation regulation in neurons?

Research has revealed that eIF-3.G plays a specialized role in shaping the neuronal protein landscape through selective binding to specific mRNAs. Key findings include:

• 5'UTR binding preference: eIF-3.G preferentially binds to GC-rich 5'UTRs of a select set of mRNAs enriched in activity-dependent functions in neurons .

• Structural impact on translation: A missense mutation in the conserved Zinc-Finger (ZF) of eIF-3.G can alter translation in a 5'UTR-dependent manner, affecting neuronal protein expression and subsequently modulating neuronal excitation .

• Selective regulation: eIF-3.G appears to selectively regulate translation of specific mRNAs beyond its general role in translation initiation, particularly those with complex 5'UTR structures. In C. elegans studies, 231 5'UTR proximal footprints were detected, mapping to 225 different genes .

• Evolutionary conservation: This selective regulation mechanism appears to be conserved between C. elegans and mammals, as suggested by comparative analysis with human eIF3g PAR-CLIP data from HEK293 cells .

What is known about eIF-3.G as an autoantigen in inflammatory myositis?

Research has identified eIF-3.G as part of a novel autoantigen complex in patients with polymyositis (PM):

• Prevalence: Anti-eIF3 autoantibodies were detected in 0.44% of PM patients (3 out of 678) and were not found in disease-specific or healthy control sera .

• Autoantibody characteristics: These autoantibodies recognize multiple subunits of the eIF3 complex, including eIF3G, eIF3I, eIF3H, eIF3E/F, eIF3L/D, eIF3B, and eIF3A .

• Clinical associations:

  • Patients with anti-eIF3 autoantibodies had no history of malignancy or interstitial lung disease

  • These patients showed a favorable response to treatment

  • The autoantibody appears to correlate with a good prognosis

• Detection methods: Anti-eIF3 autoantibodies produce a distinctive pattern in radio-labeled protein immunoprecipitation assays and demonstrate a fine cytoplasmic speckled pattern in indirect immunofluorescence .

How can researchers investigate the role of eIF-3.G mutations in neurological disorders?

To investigate eIF-3.G mutations in neurological contexts:

• Model systems approach: Utilize C. elegans as demonstrated in published research, where a missense mutation (C130Y) in the zinc finger domain was found to dampen neuronal hyperexcitation .

• Functional domains analysis: Focus on the RNA recognition motif (RRM) and zinc finger (ZF) domains, as mutations in these regions have shown functional consequences in neuronal activity regulation .

• Translational regulation assessment:

  • Implement ribosome profiling to assess translation efficiency changes

  • Use reporter constructs with different 5'UTRs to evaluate the impact of eIF-3.G mutations on translation of specific mRNAs

  • Employ polysome profiling to determine shifts in translational status of target mRNAs

• RNA binding specificity determination:

  • Apply seCLIP or similar techniques to map RNA-binding sites

  • Compare binding patterns between wild-type and mutant eIF-3.G

  • Focus on GC-rich 5'UTRs, which have shown preferential association with eIF-3.G

• Phenotypic assessment: Evaluate neuronal activity patterns, synaptic transmission, and behavioral outcomes in model organisms expressing wild-type versus mutant eIF-3.G.

What are common challenges in detecting eIF-3.G by Western blotting and how can they be overcome?

Common challenges and solutions include:

• Multiple banding patterns:

  • Problem: Non-specific bands or degradation products

  • Solution: Use freshly prepared samples with protease inhibitors and optimize blocking conditions (5% BSA may be more effective than milk for some antibodies)

• Weak signal intensity:

  • Problem: Low abundance of eIF-3.G in certain tissues or cell types

  • Solution: Increase protein loading (50-100μg total protein), extend primary antibody incubation to overnight at 4°C, or use enhanced chemiluminescence substrates

• Background noise:

  • Problem: Non-specific binding

  • Solution: Increase washing steps, optimize antibody dilution (typically 1:1000-1:2000 for commercial antibodies), and consider using TBST instead of PBST for washing

• Cross-reactivity issues:

  • Problem: Antibody detects proteins other than eIF-3.G

  • Solution: Select monoclonal antibodies with validated specificity or use knockout/knockdown controls to confirm band identity

How can researchers differentiate between direct and indirect RNA binding events in eIF-3.G studies?

To differentiate between direct and indirect RNA binding:

• Domain deletion controls: Use truncated versions of eIF-3.G lacking the RNA-binding domain (e.g., ΔRRM) as controls in CLIP experiments. This approach allows subtraction of signals representing indirect binding events, as demonstrated in neuronal eIF-3.G research .

• Competitive binding assays: Perform in vitro binding assays with purified eIF-3.G and candidate RNAs in the presence or absence of potential protein cofactors.

• UV cross-linking optimization: Adjust cross-linking conditions to favor direct protein-RNA interactions. Direct RNA-protein interactions typically form rapidly under mild UV exposure (254nm).

• Bioinformatic analysis: Apply stringent filtering criteria when analyzing sequencing data. In published research, specific footprints were defined as clusters of at least 20 high-quality reads with at least 1.5-fold change enrichment over input controls .

• In vitro validation: Confirm direct binding using electrophoretic mobility shift assays (EMSAs) with purified components.

What considerations should be made when studying eIF-3.G in different tissue types?

Tissue-specific considerations include:

• Expression level variations: eIF-3.G expression levels vary across tissues, requiring adjustment of protein loading and detection parameters. Neuronal tissues may require special consideration due to the role of eIF-3.G in neuronal protein translation .

• Complex formation differences: The composition and stability of the eIF3 complex may vary across tissues, affecting co-immunoprecipitation results and potentially requiring tissue-specific optimization of buffer conditions.

• Fixation and sample preparation: For immunohistochemistry applications:

  • Brain tissue may benefit from shorter fixation times to preserve epitope accessibility

  • Muscle tissue (relevant for myositis studies) requires optimized antigen retrieval protocols

  • Paraffin-embedded versus frozen section protocols should be selected based on the specific antibody validation data

• Background autofluorescence: Different tissues present varying levels of autofluorescence, particularly in immunofluorescence applications. This can be mitigated using specific quenching protocols or spectral unmixing during image acquisition.

• Genetic models: When using model organisms, consider tissue-specific expression systems. In published C. elegans research, successful neuron-specific expression of tagged eIF-3.G variants was achieved, allowing tissue-specific investigation of its functions .